153 related articles for article (PubMed ID: 21668852)
1. Safety and tolerability of immunotherapy using various updosing schedules of a new SCIT product with an optimised allergen/aluminium hydroxide ratio.
Jung K
Allergy; 2011 Jul; 66 Suppl 95():41-3. PubMed ID: 21668852
[TBL] [Abstract][Full Text] [Related]
2. Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio.
Pfaar O; Jung K; Wolf H; Decot E; Kleine-Tebbe J; Klimek L; Wüstenberg E
Allergy; 2012 May; 67(5):630-7. PubMed ID: 22385366
[TBL] [Abstract][Full Text] [Related]
3. An alternative allergen:adjuvant formulation potentiates the immunogenicity and reduces allergenicity of a novel subcutaneous immunotherapy product for treatment of grass-pollen allergy.
Rask C; Lund L; Lund G; Heydenreich B; Wurtzen P; Bellinghausen I; Saloga J; Lund K
Clin Exp Allergy; 2012 Sep; 42(9):1356-68. PubMed ID: 22925322
[TBL] [Abstract][Full Text] [Related]
4. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.
Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R
Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924
[TBL] [Abstract][Full Text] [Related]
5. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide.
Gadermaier E; Flicker S; Aberer W; Egger C; Reider N; Focke M; Vrtala S; Kundi M; Valenta R
Int Arch Allergy Immunol; 2010; 151(1):17-27. PubMed ID: 19672093
[TBL] [Abstract][Full Text] [Related]
8. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.
Klimek L; Schendzielorz P; Pinol R; Pfaar O
Clin Exp Allergy; 2012 Jun; 42(6):936-45. PubMed ID: 22909165
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
[TBL] [Abstract][Full Text] [Related]
10. Tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with an optimized allergen to adjuvant ratio under routine practice conditions: a noninterventional observational study.
Hauswald B; Wolf H; Becker F; Becker S; Schnitker J; Wüstenberg E
J Investig Allergol Clin Immunol; 2013; 23(7):471-7. PubMed ID: 24654311
[TBL] [Abstract][Full Text] [Related]
11. Phase II/III clinical trial to assess the tolerability and immunological effect of a new updosing phase of Dermatophagoides mix-based immunotherapy.
Tabar AI; González Delgado P; Sánchez Hernández C; Basagaña Torrento M; Moreno Benítez F; Arina M
J Investig Allergol Clin Immunol; 2015; 25(1):40-6. PubMed ID: 25898693
[TBL] [Abstract][Full Text] [Related]
12. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
13. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
Wang HY; Lin XP; Hao CL; Zhang CQ; Sun BQ; Zheng JP; Chen P; Sheng JY; Wu A; Zhong NS
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct; 29(10):679-87. PubMed ID: 17129496
[TBL] [Abstract][Full Text] [Related]
14. Dosing and efficacy in specific immunotherapy.
Demoly P; Calderon MA
Allergy; 2011 Jul; 66 Suppl 95():38-40. PubMed ID: 21668851
[TBL] [Abstract][Full Text] [Related]
15. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.
Senti G; Johansen P; Haug S; Bull C; Gottschaller C; Müller P; Pfister T; Maurer P; Bachmann MF; Graf N; Kündig TM
Clin Exp Allergy; 2009 Apr; 39(4):562-70. PubMed ID: 19226280
[TBL] [Abstract][Full Text] [Related]
16. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
[TBL] [Abstract][Full Text] [Related]
17. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually.
Panzner P; Petrás M; Sýkora T; Lesná I
Respir Med; 2008 Sep; 102(9):1296-304. PubMed ID: 18585908
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of microencapsulated timothy grass pollen extract in grass-allergic individuals.
TePas EC; Hoyte EG; McIntire JJ; Umetsu DT
Ann Allergy Asthma Immunol; 2004 Jan; 92(1):25-31. PubMed ID: 14756461
[TBL] [Abstract][Full Text] [Related]
19. Preseasonal specific immunotherapy with modified Phleum pratense allergenic extracts: tolerability and effects.
Ricca V; Ciprandi G; Pesce G; Riccio A; Varese P; Pecora S; Canonica GW
Allergol Immunopathol (Madr); 1997; 25(4):167-75. PubMed ID: 9269506
[TBL] [Abstract][Full Text] [Related]
20. [Specific immunotherapy in the treatment of patients with atopic dermatitis--results of double blind placebo controlled study].
Silny W; Czarnecka-Operacz M
Pol Merkur Lekarski; 2006 Dec; 21(126):558-65. PubMed ID: 17405298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
